Solvay Pharmaceuticals has received FDA approval for EstroGel, billed as the first-ever estrogen therapy transdermal gel in the country.

EstroGel is a clear, odorless, hydro-alcoholic gel that provides for delivery of estradiol for estrogen replacement in a non-patch transdermal form. It can be used for the treatment of moderate to severe vasomotor symptoms, as well as vulvar and vaginal atrophy associated with the menopause.

“With the approval of EstroGel, women and healthcare professionals now have an additional hormone therapy option. EstroGel will offer healthcare providers the opportunity to individualize a woman’s therapy to help manage vasomotor symptom relief,” said Solvay President and CEO Harold Shlevin. “The FDA’s approval of EstroGel provides Solvay Pharmaceuticals with a complete line of women’s health products, offering women and their healthcare professionals a range of first and second-line menopausal therapeutic options, as well as adjunctive therapy for women requiring endometrial protection.”

EstroGel has been a prescribed therapy for more than 25 years in Europe. It will be available with a prescription in pharmacies throughout the United States by mid-year.

Solvay Pharmaceuticals, based in Marietta, GA, near Atlanta, is active in the therapeutic areas of cardiology, gastroenterology, mental health and women’s health. It is a member of the worldwide Solvay Group of chemical and pharmaceutical companies, headquartered in Brussels, Belgium.

Solvay Pharmaceuticals: